

UCLA

UCLA Previously Published Works

Title

Corticotrophin-releasing factor 1 activation in the central amygdale and visceral hyperalgesia

Permalink

<https://escholarship.org/uc/item/4265k0kh>

Journal

Neurogastroenterology & Motility, 27(1)

ISSN

1350-1925

Author

Taché, Y

Publication Date

2015

DOI

10.1111/nmo.12495

Peer reviewed



Published in final edited form as:

Neurogastroenterol Motil. 2015 January ; 27(1): 1–6. doi:10.1111/nmo.12495.

Corticotrophin-releasing factor 1 activation in the central amygdale and visceral hyperalgesia

Y. TACHÉ

Center for Neurobiology of Stress & Women's Health and CURE: Digestive Diseases Research Center, Digestive Diseases Division, UCLA David Geffen School of Medicine and VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA

Abstract

Corticotropin-releasing factor (CRF)-CRF₁ receptor in the brain plays a key role in stress-related alterations of behavior including anxiety/depression, and autonomic and visceral functions. In particular, CRF₁ signaling mediates hypersensitivity to colorectal distension (CRD) in various models (early life adverse events, repeated psychological stress, chronic high anxiety, postcolonic inflammation, or repeated nociceptive CRD). So far, knowledge of brain sites involved is limited. A recent article demonstrates in rats that CRF microinjected into the central amygdala (CeA) induces a hyperalgesic response to CRD and enhances the noradrenaline and dopamine levels at this site. The visceral and noradrenaline, unlike dopamine, responses were blocked by a CRF₁ antagonist injected into the CeA. Here, we review the emerging role that CRF-CRF₁ signaling plays in the CeA to induce visceral hypersensitivity. In the somatic pain field, CRF in the CeA was shown to induce pain sensitization. This is mediated by the activation of postsynaptic CRF₁ receptors and protein kinase A signaling that increases N-methyl-D-aspartate receptor neurotransmission. In addition, the activation of tetraethylammonium-sensitive ion channels such as Kv3 accelerates repolarization and firing rate. Whether facilitation of pain transmission underlies CRF action in the CeA-induced visceral hypersensitivity will need to be delineated. CRF₁ signaling in the CeA is also an important component of the neuronal circuitry inducing anxiety-like behavior and positioned at the interphase of the reciprocal relationship between pain and affective state. The hyperactivity of this system may represent the neuroanatomical and biochemical substrate contributing to the coexpression of hypersensitivity to CRD and mood disorders in subsets of irritable bowel syndrome patients.

Keywords

central amygdala; CRF; CRF₁; antagonists; noradrenaline; stress; visceral hyperalgesia

© 2014 John Wiley & Sons Ltd

Address for Correspondence: Y. Taché, CURE: Digestive Diseases Research Center, Building 115, Room 117, VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA. Tel: 310-312-9275; fax: 1-310-268-4963; ytache@mednet.ucla.edu.

DISCLOSURE

No competing disclosure.

INTRODUCTION

Guillemin and Schally *et al.* reported independently in the mid 1950 the existence of the hypothalamic factor able to stimulate adrenocorticotrophic hormone (ACTH) release from the pituitary gland in rats.¹ The substance contained in hypothalamic extracts was named corticotropin- releasing factor (CRF) in line with its releasing action on ACTH secretion and the fact that its chemical structure was yet to be identified.¹ In 1981, after decades of research, Vale (a former PhD student of Guillemin),² and his group succeeded to report the sequence of ovine CRF as a 41- amino acid peptide.³ Soon after the isolation of CRF, the same group discovered genes encoding three paralogs, urocortin 1, urocortin 2, and urocortin 3, cloned their cognate receptors (CRF₁ and CRF₂) and developed the first peptide CRF₁/CRF₂ antagonists, α -helical CRF₉₋₄₁.⁴ Corticotropin-releasing factor was established to bind with high and moderate affinity to CRF₁ and CRF₂ receptors, while urocortin 1 displays high-affinity to both G-protein coupled receptors and urocortin 2 and 3 are selective CRF₂ receptor agonists.⁴ Both CRF₁ and CRF₂ receptors are coupled to similar transduction mechanisms typically the activation of cyclic adenosine monophosphate-protein kinase A (PKA) signal transduction pathway although it encompasses coupling to diverse intracellular network in a tissue-specific manner.⁵ All these successive milestone breakthroughs fostered research to unravel the biochemical coding of stress.⁴

It was unambiguously established that CRF initiates the hypothalamic-pituitary-adrenocortical (HPA) response to various stressors by binding CRF₁ receptors in the anterior pituitary after its release into the portal blood.⁶ However, CRF action in the brain expands far beyond mediating the endocrine component of stress. This was in keeping with CRF-CRF₁ system being widely distributed in stress-responsive extra-hypothalamic brain areas, including the neocortex, extended amygdala, medial septum, hippocampus, thalamus, and autonomic midbrain and hindbrain nuclei.⁷ Convergent reports showed that CRF injected intracerebroventricularly (icv) recapitulates and coordinates the overall bodily response to acute stress including the alterations of gastrointestinal secretory motor function.^{8–10} Furthermore, blocking CRF₁ receptors by pharmacological or transgenic approaches dampened stress-related behavioral changes including anxiety/ depression, hypervigilance and autonomic and visceral alterations in several experimental species.^{10–13} Subsequent extensive preclinical data indicated that dys-regulation of the CRF-CRF₁ system is implicated in the etiology and maintenance of several stress-sensitive disorders as recently reviewed.^{14–17} Among those, irritable bowel syndrome (IBS) is manifested by chronic abdominal pain, altered bowel habits in the absence of detectable organic diseases.¹⁸ Stressors of psychosocial, physical, or immune origin serve as triggers for the onset or exacerbation of IBS symptoms.¹⁹ In particular, early adverse life events in the form of emotional, sexual, or physical abuse are also major predisposing factors for the development of IBS later in life.¹⁹ In addition, psychiatric comorbidity, namely anxiety and depression, affects IBS patients, reaching 40–90% in tertiary care centers.²⁰ As recurrent abdominal pain is the hallmark symptom of IBS,¹⁸ a number of studies focused to delineate whether the brain CRF₁ signaling system underpins stress-related enhancement of visceral pain in experimental models.²¹

BRAIN CRF₁ RECEPTOR: ROLE IN VISCERAL HYPERSENSITIVITY

The initial report by Gué *et al.*²² showed that icv injection of CRF induced visceral hypersensitivity to colorectal distension (CRD) in rats, mimicking the effect of 2-h partial restraint stress. Furthermore, the icv injection of the CRF₁/CRF₂ antagonists, α -helical CRF₉₋₄₁ prevented the effect of restraint stress providing the first evidence pointing to the involvement of central CRF signaling in acute stress-related development of visceral hypersensitivity.²² With the emergence of number of selective CRF₁ antagonist,¹¹ visceral pain studies were performed in adult rats using peripheral administration of NBI-35965,²³ CP-154,526,²⁴⁻²⁷ antalarmin,²⁸⁻³¹ JTC-017,³² NBI-30775,³³ DMP-696,³⁴ NGD 98-2, or NGD 9002.³⁵ Convergent findings supported the involvement of CRF₁ subtype in the hypersensitivity to CRD induced by icv CRF^{28,35} and occurring in a variety of rodent models.²¹ Those included acute or repeated exposure to water avoidance stress combined with neonatal maternal separation,^{23,25,34} or consecutive sets of nociceptive CRD,^{24,25,29,32,35} or repeated daily CRD performed at 6 weeks after the development of colitis,²⁷ intracolonic infusion of 0.5% acetic acid,³⁶ or a high-anxiety rat strain, the Wistar Kyoto (WKO).^{28,30} Of relevance was the demonstration that chronic treatment with CP-154,526, alleviated the development and maintenance of visceral hyperalgesia induced in a model of repeated intermittent psychological stress.²⁶ It is important to note that the CRF system is not active under basal conditions as CRF₁ antagonists had no effect of their own in these studies. Consistent with the pharmacological approach, genetically modified mice with deletion of CRF₁ receptors displayed a reduction of visceral motor response to phasic CRD.³³ These compelling preclinical reports indicate that the CRF₁ signaling plays a critical role in the visceral hypersensitivity occurring in the context of early life adverse events, repeated psychological stress, a model of chronic high anxiety and peripherally initiated mechanisms following remission of colonic inflammation or repeated nociceptive activation of colonic mechanoreceptors. However, because all available selective CRF₁ antagonists are small hydrophobic molecules designed to cross the blood brain barrier,¹¹ their peripheral administration in the above studies did not provide insight to specific brain nuclei involved in preventing the hyperalgesia.

THE CENTRAL AMYGDALA AS A BRAIN SITE OF CRF₁ ANTAGONIST ACTION

So far the investigation of brain sites at which the CRF-CRF₁ system modulates visceral hypersensitivity has remained limited^{32,37} compared to the knowledge of brain nuclei responsive to CRF-induced alterations of gut motor function.³⁸ One study showed that the CRF₁/CRF₂ antagonist, α -helical CRF₉₋₄₁ microinjected into the hippocampus reduces abdominal contraction frequency induced by tonic CRD at maximal nociceptive range in rats.³² Another study points to the central amygdala (CeA) as a responsive site to the CRF₁ antagonist, CP-376395 to dampen the visceral hypersensitivity to CRD at pressure >30 mmHg in the WKO rat strain.³⁷ In this issue of *Neurogastroenterology and Motility*, the article by Su *et al.*³⁹ demonstrated that CRF microinjected into the CeA increased sensitivity to CRD performed at 20–80 mmHg in Wistar rats and the response was blocked by intra-CeA injection of CP-15426. This provides the first evidence demonstrating the modulation

of visceral pain by CRF-CRF₁ receptor at this site.³⁹ In support of a role of endogenous CRF as ligand to act on CRF₁ receptor is neuroanatomical evidence that the CeA is a major extrahypothalamic source of CRF. The peptide is expressed in neuronal cell bodies with axons projecting to widespread regions of the basal forebrain and pontine/brainstem including the locus coeruleus (LC).^{40,41} Additionally, CRF-like immunoreactivity and gene expression in CeA are increased in response to CRD⁴² and various conditions inducing visceral pain or hyperalgesia.^{43–46} While the CeA is just becoming recognized as a key element of circuitry through which CRF activating CRF₁ receptor induces visceral hypersensitivity, in the somatic pain field, accumulated evidence from biochemical,⁴⁴ behavioral, and electrophysiological studies⁴⁷ established previously that endogenous CRF-CRF₁ signaling in this limbic nucleus stimulates pain sensitization.⁴⁸ For instance, CRF₁ antagonists such as NBI-27914, MPZP or R121919 microinjected into the CeA exert antinociceptive effect to mechanical stimulation in a model of arthritis pain and attenuated mechanical hypersensitivity and thermal hyperalgesia occurring during the withdrawal of substance abuse.^{43,49–52}

Corticotropin-releasing factor-CRF₁ signaling in the CeA is also a well-established key component of the neuronal circuitry contributing to anxiety-like behavior⁴⁷ and is positioned to drive the reciprocal relationship between pain and affective state.⁵³ Based on these preclinical data, it can be speculated that overactivity of the CRF-CRF₁ in the CeA may underlie the comorbidity of subset of IBS patients who display hypersensitivity to CRD⁵⁴ and mood disorders.⁵⁵ A recent clinical study using functional magnetic resonance imaging showed that an acute oral administration of the CRF₁ antagonist, GW 876008 dampened the amygdala activation produced by the anticipation of visceral pain compared to placebo drug in IBS female patients.⁵⁶ Whether the existing or newly developed CRF₁ antagonists¹¹ will progress to show therapeutic benefits for stress-sensitive visceral hyperalgesia in subsets of IBS is still a work in progress. An early clinical trial involving IBS patients with diarrhea did not show beneficial effect of oral administration of the CRF₁ antagonist paxacerfont (BMS-562086) on IBS symptoms although a dose-related trend to reduce pain was observed.⁵⁷

MECHANISMS INVOLVED IN CRF-CRF₁ MEDIATED MODULATION OF VISCERAL HYPERSENSITIVITY IN THE CENTRAL AMYGDALA

The underlying neuronal mechanisms through which the blockade of CRF₁ receptor in the CeA alleviates the development of visceral hyperalgesia still remain unknown. The latero-capsular division of the CeA is defined as the ‘nociceptive amygdala’ as it receives nociceptive-specific input directly from the parabrachial area through the spinal-parabrachial-amygdaloid pathway.⁵³ Studies in the somatic pain field established that CRF in the latero-capsular subdivision of CeA facilitates synaptic transmission of pain. Whole-cell patch-clamp recording of CeA neurons located in the latero-capsular division in brain slices established that CRF acts on postsynaptic CRF₁ receptors leading to protein kinase A dependent increases of *N*-methyl-D-aspartate (NMDA) receptor transmission. There is also a CRF₁-mediated activation of tetraethylammonium-sensitive ion channels such as Kv3 that accelerates action potential repolarization and increases firing rate.^{47,51,52} Under condition

of chronic somatic pain hypersensitivity, there is also evidence that CRF₁ receptors ‘switch on’ silent NMDA receptors through PKA-dependent mechanisms in the CeA.⁵² Additional studies in genetically modified mice with selective deletion of CRF₁ receptors on glutaminergic neurons in the CeA clearly demonstrated that CRF facilitates excitatory transmission by a CRF₁-mediated direct action on glutaminergic neurons.¹³ Whether similar cellular mechanisms are involved in CRF-CRF₁ mediated visceral hyperalgesia in the CeA will be relevant avenues to investigate.

In addition to the critical role that CRF₁ receptors expressed on glutaminergic neurons of the CeA play,^{13,58} there is evidence that catecholamine signaling may also regulate CeA glutaminergic transmission.⁵⁸ Several studies indicate that various stressors increase extracellular noradrenaline in the CeA.⁵⁹ In this issue of *Neurogastroenterology and Motility*, Su *et al.*³⁹ showed that CRD increases levels of noradrenaline in the CeA and the response is enhanced by CRF injected intra-CeA. These changes are CRF₁ mediated as shown by the blockade of CP-15426.³⁹ Of interest was the specificity of CRF-CRF₁ action to noradrenaline. The heightened levels of dopamine in the CeA induced by CRF were unchanged by CP-15426 while 5-HT levels were not modified by either treatment.³⁹ The pronounced interaction of CRF and catecholaminergic systems during stress has been established early on as a feed-forward mechanism taking place at multiple levels of the pons and basal forebrain, whereby CRF activates noradrenaline that in turn activates CRF.⁶⁰ The CeA received input from LC catecholaminergic nuclei.⁶¹ We previously reported that colonic distension at nociceptive range markedly activates catecholaminergic neurons in the ventrolateral medulla (A1/C1), nucleus tractus solitarius (A2/C2), and LC cell group as shown by double labeling of Fos and tyrosine hydroxylase.⁶² In addition the activation of LC noradrenergic neurons by CRD are prevented by systemic injection of the CRF₁ antagonist, NBI 35965 as shown by electrophysiological recording.⁶³ Whether the activated noradrenergic neurons in the LC contributes to the increased levels of noradrenaline after CRD through their projections to the CeA⁶¹ remains to be established. Still to be addressed is whether changes in noradrenaline levels by intra-CeA after injection of CRF contribute to the visceral hyperalgesia. Recent studies showed that β -adrenergic receptor activation in the CeA could increase presynaptic glutamate release^{58,59} while α_2 – adrenergic receptor agonist inhibits CeA excitability and induces somatic antinociception.⁶⁴

Acknowledgments

FUNDING

Supported by NIHDDK-41303 (Animal core), NIHDDK-57238, and Veterans Administration Research Career Scientist Award.

References

- Guillemin R. Neuroendocrinology: a short historical review. *Ann N Y Acad Sci.* 2011; 1220:1–5. [PubMed: 21388398]
- Bale TL, Chen A. Minireview: CRF and Wylie Vale: a story of 41 amino acids and a Texan with grit. *Endocrinology.* 2012; 153:2556–61. [PubMed: 22492308]

3. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β -endorphin. *Science*. 1981; 213:1394–7. [PubMed: 6267699]
4. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. *Ann N Y Acad Sci*. 1999; 885:312–28. [PubMed: 10816663]
5. Grammatopoulos DK. Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. *Br J Pharmacol*. 2012; 166:85–97. [PubMed: 21883143]
6. Turnbull AV, Rivier C. Corticotropin-releasing factor (CRF) and endocrine response to stress: CRF receptors, binding protein, and related peptides. *Proc Soc Exp Biol Med*. 1997; 215:1–10. [PubMed: 9142133]
7. Wang L, Goebel-Stengel M, Stengel A, Wu SV, Ohning G, Taché Y. Comparison of CRF-immunoreactive neurons distribution in mouse and rat brains and selective induction of Fos in rat hypothalamic CRF neurons by abdominal surgery. *Brain Res*. 2011; 1415:34–46. [PubMed: 21872218]
8. Bale TL, Vale WW. CRF and CRF receptor: role in stress responsivity and other behaviors. *Annu Rev Pharmacol Toxicol*. 2004; 44:525–57. [PubMed: 14744257]
9. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. *Proc Natl Acad Sci U S A*. 2000; 97:6079–84.
10. Stengel A, Taché Y. Corticotropin-releasing factor signaling and visceral response to stress. *Exp Biol Med (Maywood)*. 2010; 235:1168–78. [PubMed: 20881321]
11. Zorrilla EP, Koob GF. Progress in corticotropin-releasing factor-1 antagonist development. *Drug Discov Today*. 2010; 15:371–83. [PubMed: 20206287]
12. Hummel M, Cummons T, Lu P, Mark L, Harrison JE, Kennedy JD, Whiteside GT. Pain is a salient “stressor” that is mediated by corticotropin-releasing factor-1 receptors. *Neuropharmacology*. 2010; 59:160–6. [PubMed: 20470804]
13. Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, Vogl AM, Dedic N, Schumacher M, von Wolff G, et al. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. *Science*. 2011; 333:1903–7. [PubMed: 21885734]
14. Zorrilla EP, Logrip ML, Koob GF. Corticotropin releasing factor: a key role in the neurobiology of addiction. *Front Neuroendocrinol*. 2014; 35:234–44. [PubMed: 24456850]
15. Taché Y, Brunnhuber S. From Hans Selye’s discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases. *Ann N Y Acad Sci*. 2008; 1148:29–41. [PubMed: 19120089]
16. Gravanis A, Margioris AN. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. *Curr Med Chem*. 2005; 12:1503–12. [PubMed: 15974983]
17. Holsboer F, Ising M. Central CRH system in depression and anxiety—evidence from clinical studies with CRH1 receptor antagonists. *Eur J Pharmacol*. 2008; 583:350–7. [PubMed: 18272149]
18. Khan S, Chang L. Diagnosis and management of IBS. *Nat Rev Gastroenterol Hepatol*. 2010; 7:565–81. [PubMed: 20890316]
19. Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. *Gastroenterology*. 2011; 140:761–5. [PubMed: 21256129]
20. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. *Clin Ther*. 2010; 32:1221–33. [PubMed: 20678672]
21. Larauche M, Mulak A, Taché Y. Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study. *J Neurogastroenterol Motil*. 2011; 17:213–34. [PubMed: 21860814]
22. Gué M, Del Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J, Bueno L. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. *Neurogastroenterol Motil*. 1997; 9:271–9. [PubMed: 9430796]
23. Million M, Grigoriadis DE, Sullivan S, Crowe PD, McRoberts JA, Zhou H, Saunders PR, Mailliot C, et al. A novel water-soluble selective CRF₁ receptor antagonist, NBI 35965, blunts stress-

- induced visceral hyperalgesia and colonic motor function in rats. *Brain Res.* 2003; 985:32–42. [PubMed: 12957366]
24. Schwetz I, Bradesi S, McRoberts JA, Bradesi S, Gale G, Fanselow M, Million M, Ohning G, et al. Delayed stress-induced colonic hypoersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin releasing factor-1 receptors. *Am J Physiol Gastrointest Liver Physiol.* 2004; 286:G683–91. [PubMed: 14615283]
 25. Schwetz I, McRoberts JA, Coutinho SV, Bradesi S, Gale G, Fanselow M, Million M, Ohning G, et al. Corticotropin- releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats. *Am J Physiol Gastrointest Liver Physiol.* 2005; 289:G704–12. [PubMed: 15994424]
 26. Larauche M, Bradesi S, Million M, McLean P, Taché Y, Mayer EA, McRoberts JA. Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. *Am J Physiol Gastrointest Liver Physiol.* 2008; 294:G1033–40. [PubMed: 18308857]
 27. Saito-Nakaya K, Hasegawa R, Nagura Y, Ito H, Fukudo S. Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. *Neurogastroenterol Motil.* 2008; 20:1147–56. [PubMed: 18761632]
 28. Greenwood-Van Meerveld B, Johnson AC, Cochrane S, Schulkin J, Myers DA. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. *Neurogastroenterol Motil.* 2005; 17:415–22. [PubMed: 15916629]
 29. Million M, Maillot C, Adelson DW, Nozu T, Gauthier A, Rivier J, Chrousos GP, Bayati A, et al. Peripheral injection of sauvagine prevents repeated colorectal distension-induced visceral pain in female rats. *Peptides.* 2005; 26:1188–95. [PubMed: 15949637]
 30. Buckley MM, O'Halloran KD, Rae MG, Dinan TG, O'malley D. Modulation of enteric neurons by interleukin- 6 and corticotropin-releasing factor contributes to visceral hypersensitivity and altered colonic motility in a rat model of irritable bowel syndrome. *J Physiol.* 2014; 592:5235–50. [PubMed: 25260633]
 31. Smith C, Nordstrom E, Sengupta JN, Miranda A. Neonatal gastric suctioning results in chronic visceral and somatic hyperalgesia: role of corticotropin releasing factor. *Neurogastroenterol Motil.* 2007; 19:692–9. [PubMed: 17640185]
 32. Saito K, Kasai T, Nagura Y, Ito H, Kanazawa M, Fukudo S. Corticotropin- releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distention in rats. *Gastroenterology.* 2005; 129:1533–43. [PubMed: 16285953]
 33. Trimble N, Johnson AC, Foster A, Greenwood-Van Meerveld B. Corticotropin- releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity. *Neurogastroenterol Motil.* 2007; 19:754–60. [PubMed: 17539891]
 34. Bradesi S, Martinez V, Lao L, Larsson H, Mayer EA. Involvement of vasopressin 3 receptors in chronic psychological stress-induced visceral hyperalgesia in rats. *Am J Physiol Gastrointest Liver Physiol.* 2009; 296:G302–9. [PubMed: 19033533]
 35. Million M, Zhao JF, Luckey A, Maynard GD, Kehne J, Hoffman DC, Taché Y. The newly developed CRF1-receptor antagonists, NGD 98- 2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats. *PLoS ONE.* 2013; 8:e73749. [PubMed: 24040053]
 36. Jia FY, Li XL, Li TN, Wu J, Xie BY, Lin L. Role of nesfatin-1 in a rat model of visceral hypersensitivity. *World J Gastroenterol.* 2013; 19:3487–93. [PubMed: 23801843]
 37. Johnson AC, Tran L, Schulkin J, Greenwood-Van Meerveld B. Importance of stress receptor-mediated mechanisms in the amygdala on visceral pain perception in an intrinsically anxious rat. *Neurogastroenterol Motil.* 2012; 24:479–86. e219. [PubMed: 22364507]
 38. Taché Y, Bonaz B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. *J Clin Invest.* 2007; 117:33–40. [PubMed: 17200704]
 39. Su J, Tanaka Y, Muratsubaki T, Kano M, Kanazawa M, Fukudo S. Injection of corticotropin-releasing hormone into the amygdala aggravates visceral nociception and induces noradrenaline release in rats. *Neurogastroenterol Motil.* 2014; 27:30–9. [PubMed: 25359531]

40. Van Bockstaele EJ, Colago EE, Valentino RJ. Amygdaloid corticotropin-releasing factor targets locus coeruleus dendrites: substrate for the coordination of emotional and cognitive limbs of the stress response. *J Neuroendocrinol.* 1998; 10:743–57. [PubMed: 9792326]
41. Gray TS. Amygdaloid CRF pathways. Role in autonomic, neuroendocrine, and behavioral responses to stress. *Ann N Y Acad Sci.* 1993; 697:53–60. [PubMed: 8257022]
42. Kim SH, Han JE, Hwang S, Oh DH. The expression of corticotropin-releasing factor in the central nucleus of the amygdala, induced by colorectal distension, is attenuated by general anesthesia. *J Korean Med Sci.* 2010; 25:1646–51. [PubMed: 21060755]
43. Ji G, Fu Y, Ruppert KA, Neugebauer V. Pain-related anxiety-like behavior requires CRF1 receptors in the amygdala. *Mol Pain.* 2007; 3:13. [PubMed: 17550594]
44. Rouwette T, Klemann K, Gaszner B, Scheffer GJ, Roubos EW, Scheenen WJ, Vissers K, Kozicz T. Differential responses of corticotropin-releasing factor and urocortin 1 to acute pain stress in the rat brain. *Neuroscience.* 2011; 183:15–24. [PubMed: 21463663]
45. Greenwood-Van Meerveld B, Johnson AC, Schulkin J, Myers DA. Long-term expression of corticotropin-releasing factor (CRF) in the paraventricular nucleus of the hypothalamus in response to an acute colonic inflammation. *Brain Res.* 2006; 1071:91–6. [PubMed: 16423333]
46. Nishii H, Nomura M, Aono H, Fujimoto N, Matsumoto T. Up-regulation of galanin and corticotropin-releasing hormone mRNAs in the key hypothalamic and amygdaloid nuclei in a mouse model of visceral pain. *Regul Pept.* 2007; 141:105–12. [PubMed: 17335920]
47. Ji G, Neugebauer V. Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. *J Neurophysiol.* 2007; 97:3893–904. [PubMed: 17392412]
48. Rouwette T, Vanelderen P, Roubos EW, Kozicz T, Vissers K. The amygdala, a relay station for switching on and off pain. *Eur J Pain.* 2012; 16:782–92. [PubMed: 22337528]
49. Cohen A, Treweek J, Edwards S, Leão RM, Schulteis G, Koob GF, George O. Extended access to nicotine leads to a CRF receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. *Addict Biol.* 2013 [Epub ahead of print]. 10.1111/adb.12077
50. Baiamonte BA, Valenza M, Roltsch EA, Whitaker AM, Baynes BB, Sabino V, Gilpin NW. Nicotine dependence produces hyperalgesia: role of corticotropin- releasing factor-1 receptors (CRF1Rs) in the central amygdala (CeA). *Neuropharmacology.* 2014; 77:217–23. [PubMed: 24107576]
51. Ji G, Fu Y, Adwanikar H, Neugebauer V. Non-pain-related CRF1 activation in the amygdala facilitates synaptic transmission and pain responses. *Mol Pain.* 2013; 9:2. [PubMed: 23410057]
52. Fu Y, Neugebauer V. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior. *J Neurosci.* 2008; 28:3861–76. [PubMed: 18400885]
53. Neugebauer V, Li W, Bird GC, Han JS. The amygdala and persistent pain. *Neuroscientist.* 2004; 10:221–34. [PubMed: 15155061]
54. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, Verrier P, Poitras P. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. *Gastroenterology.* 2002; 122:1771–7. [PubMed: 12055583]
55. North CS, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. *World J Gastroenterol.* 2007; 13:2020–7. [PubMed: 17465442]
56. Hubbard CS, Labus JS, Bueller J, Stains J, Suyenobu B, Dukes GE, Kelleher DL, Tillisch K, et al. Corticotropin- releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional- arousal circuit during expectation of abdominal pain. *J Neurosci.* 2011; 31:12491–500. [PubMed: 21880911]
57. Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, Croop R, Tong G, Dockens R, et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in females with irritable bowel syndrome? *Am J Physiol Gastrointest Liver Physiol.* 2009; 296:G1299–306. [PubMed: 19342506]

58. Silberman Y, Winder DG. Corticotropin releasing factor and catecholamines enhance glutamatergic neurotransmission in the lateral subdivision of the central amygdala. *Neuropharmacology*. 2013; 70:316–23. [PubMed: 23470280]
59. Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, Satoh M. Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. *Psychopharmacology*. 2003; 170:80–8. [PubMed: 12768272]
60. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. *Biol Psychiatry*. 1999; 46:1167–80. [PubMed: 10560023]
61. Kravets JL, Reyes BA, Unterwald EM, Van Bockstaele EJ. Direct targeting of peptidergic amygdalar neurons by noradrenergic afferents: linking stress-integrative circuitry. *Brain Struct Funct*. 2013 [Epub ahead of print]. 10.1007/s00429-013-0674-8
62. Wang L, Martinez V, Larauche M, Taché Y. Proximal colon distension induces Fos expression in oxytocin-, vasopressin-, CRF- and catecholamines- containing neurons in rat brain. *Brain Res*. 2009; 1247:79–91. [PubMed: 18955037]
63. Kosoyan H, Grigoriadis D, Taché Y. The CRF₁ antagonist, NBI-35965 abolished the activation of locus coeruleus by colorectal distension and intracisternal CRF in rats. *Brain Res*. 2004; 1056:85–96. [PubMed: 16095571]
64. Ortiz JP, Heinricher MM, Selden NR. Noradrenergic agonist administration into the central nucleus of the amygdala increases the tail-flick latency in lightly anesthetized rats. *Neuroscience*. 2007; 148:737–43. [PubMed: 17706366]

Key Messages

This review describes the role of CRF-CRF₁ receptor signaling in experimental models of visceral hyperalgesia with a focus on brain sites and mechanisms of action in the central amygdala.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript